NASDAQ:TECH - BIO-TECHNE Stock Price, News & Analysis

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE announced a quarterly dividend on Tuesday, August 6th. Shareholders of record on Friday, August 16th will be given a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 annualized dividend and a yield of 0.68%. The ex-dividend date of this dividend is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported $1.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.08. The biotechnology company had revenue of $191.66 million for the quarter, compared to analyst estimates of $196.37 million. BIO-TECHNE had a return on equity of 13.20% and a net margin of 13.45%. The firm's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.34 EPS. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

5 brokerages have issued 1 year price targets for BIO-TECHNE's shares. Their forecasts range from $165.00 to $270.00. On average, they anticipate BIO-TECHNE's share price to reach $204.80 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Press coverage about TECH stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 771,200 shares, an increase of 35.4% from the June 30th total of 569,700 shares. Based on an average daily volume of 144,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 2.1% of the company's shares are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), Amgen (AMGN), Illumina (ILMN), AbbVie (ABBV), General Electric (GE), Thermo Fisher Scientific (TMO) and Akorn (AKRX).

BIO-TECHNE's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.06%), BlackRock Inc. (10.06%), Vanguard Group Inc. (9.27%), Brown Capital Management LLC (4.33%), Bamco Inc. NY (4.14%) and Janus Henderson Group PLC (3.65%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Karen A Holbrook, Norman David Eansor, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, First Trust Advisors LP, Schroder Investment Management Group, Kornitzer Capital Management Inc. KS, Citadel Advisors LLC, Brown Capital Management LLC, Bank of America Corp DE and Riverbridge Partners LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, BNP Paribas Arbitrage SA, Vanguard Group Inc., Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, DekaBank Deutsche Girozentrale and Pacer Advisors Inc.. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $187.62.

BIO-TECHNE has a market capitalization of $7.11 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,000 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]